Cover Image
市場調查報告書

中耳炎:開發中產品分析

Otitis Media - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 232857
出版日期 內容資訊 英文 86 Pages
訂單完成後即時交付
價格
Back to Top
中耳炎:開發中產品分析 Otitis Media - Pipeline Review, H2 2016
出版日期: 2016年07月20日 內容資訊: 英文 86 Pages
簡介

中耳炎的症狀有耳朵疼痛,睡眠困難,平衡感覺障礙,發熱,頭痛,食慾不振等。這個疾病患病的風險要素有高齡化,季節要素,香煙及曝露於嚴重的大氣污染等。

本報告提供全球開發平台中的中耳炎治療藥概要,提供您目前開發平台狀況和最新趨勢,後期階段及中止計劃的資訊,主要企業及他們開發中的產品評估等。

簡介

  • 調查範圍

中耳炎概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

中耳炎:企業開發中的治療藥

中耳炎:大學/機關研究中的治療藥

中耳炎:開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

中耳炎:企業開發中的產品

中耳炎:大學/機關研究中的產品

中耳炎的治療藥的開發企業

  • GlaxoSmithKline plc
  • Cubist Pharmaceuticals, Inc.
  • Yuhan Corporation
  • Arbor Pharmaceuticals, LLC.
  • Otonomy, Inc.
  • Cellceutix Corporation
  • Serum Institute of India Limited
  • ContraFect Corporation
  • BCO Pharma Ltd
  • Otitis Media

中耳炎:治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • ciprofloxacin SR
  • AR-01
  • GSK-2189242A
  • betahistine hydrochloride
  • SIILPCV-10
  • P-13
  • brilacidin
  • solithromycin
  • Recombinant Peptide to Inhibit DNA for Otitis Media and Haemophilus Influenzae Infections
  • BCO-002
  • YH-1177
  • CF-309

中耳炎:最近的開發平台趨勢

中耳炎:暫停中的計劃

中耳炎:產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8236IDB

Summary

Global Markets Direct's, 'Otitis Media - Pipeline Review, H2 2016', provides an overview of the Otitis Media pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Otitis Media, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Otitis Media and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Otitis Media
  • The report reviews pipeline therapeutics for Otitis Media by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Otitis Media therapeutics and enlists all their major and minor projects
  • The report assesses Otitis Media therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Otitis Media

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Otitis Media
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Otitis Media pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Otitis Media Overview
  • Therapeutics Development
    • Pipeline Products for Otitis Media - Overview
    • Pipeline Products for Otitis Media - Comparative Analysis
  • Otitis Media - Therapeutics under Development by Companies
  • Otitis Media - Therapeutics under Investigation by Universities/Institutes
  • Otitis Media - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Otitis Media - Products under Development by Companies
  • Otitis Media - Products under Investigation by Universities/Institutes
  • Otitis Media - Companies Involved in Therapeutics Development
    • Cellceutix Corporation
    • ContraFect Corporation
    • GlaxoSmithKline Plc
    • Lee's Pharmaceutical Holdings Limited
    • Madam Therapeutics B.V.
    • Merck & Co., Inc.
    • MerLion Pharmaceuticals Pte Ltd
    • Oticpharma Ltd
    • Otonomy, Inc.
    • Yuhan Corporation
  • Otitis Media - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (dexamethasone acetate + piperacillin sodium + tazobactam sodium) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • betahistine dihydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • brilacidin tetrahydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CF-303 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CF-309 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ciprofloxacin hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ciprofloxacin hydrochloride SR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • finafloxacin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GSK-2189242A - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pazufloxacin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PCL-1402 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Peptide to Inhibit DNA for Otitis Media and Haemophilus Influenzae Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules for Otitis Media - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • solithromycin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Otitis Media - Dormant Projects
  • Otitis Media - Product Development Milestones
    • Featured News & Press Releases
      • May 20, 2016: Otonomy Announces Assignment of C Code and Pass-Through Payment Status for OTIPRIO
      • May 16, 2016: Otonomy Announces OTIPRIO Data Presentation and Symposium at Combined Otolaryngology Spring Meetings
      • Mar 18, 2016: Otonomy Announces Publication of OTIPRIO Phase 3 Clinical Trial Results in JAMA Otolaryngology
      • Mar 03, 2016: Otonomy Initiates Phase 2 Clinical Trial of OTIPRIO in Pediatric Patients With Acute Otitis Media With Tympanostomy Tubes
      • Mar 02, 2016: Otonomy Announces Commercial Availability of OTIPRIO
      • Dec 11, 2015: Otonomy Announces FDA Approval of OTIPRIO for the Treatment of Pediatric Patients Undergoing Tympanostomy Tube Placement Surgery
      • Nov 03, 2015: Otonomy Initiates Open-Label Clinical Trial for OTIPRIO in Pediatric Patients With History of Otitis Media Requiring Tympanostomy Tubes
      • Sep 24, 2015: Otonomy to Present Results for AuriPro Phase 3 Clinical Trials at 2015 AAO-HNSF Annual Meeting
      • May 07, 2015: Otonomy Completes Enrollment in Phase 2 Clinical Trial for AuriPro in Pediatric Patients With Acute Otitis Media With Tympanostomy Tubes
      • Apr 28, 2015: Otonomy Announces FDA Acceptance of AuriPro New Drug Application
      • Apr 27, 2015: Otonomy Presents AuriPro Phase 3 Results at American Society of Pediatric Otolaryngology Conference
      • Apr 21, 2015: Otonomy to Present AuriPro Phase 3 Results at American Society of Pediatric Otolaryngology Conference
      • Mar 26, 2015: Otonomy Initiates Phase 2 Clinical Trial for AuriPro in Label Expansion Indication
      • Feb 26, 2015: Otonomy Submits New Drug Application to the FDA for AuriPro
      • Jul 08, 2014: Otonomy Announces Positive Results from Two Phase 3 Trials of AuriPro in Pediatric Patients Undergoing Ear Tube Placement Surgery
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Otitis Media, H2 2016
  • Number of Products under Development for Otitis Media - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Otitis Media - Pipeline by Cellceutix Corporation, H2 2016
  • Otitis Media - Pipeline by ContraFect Corporation, H2 2016
  • Otitis Media - Pipeline by GlaxoSmithKline Plc, H2 2016
  • Otitis Media - Pipeline by Lee's Pharmaceutical Holdings Limited, H2 2016
  • Otitis Media - Pipeline by Madam Therapeutics B.V., H2 2016
  • Otitis Media - Pipeline by Merck & Co., Inc., H2 2016
  • Otitis Media - Pipeline by MerLion Pharmaceuticals Pte Ltd, H2 2016
  • Otitis Media - Pipeline by Oticpharma Ltd, H2 2016
  • Otitis Media - Pipeline by Otonomy, Inc., H2 2016
  • Otitis Media - Pipeline by Yuhan Corporation, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Otitis Media - Dormant Projects, H2 2016

List of Figures

  • Number of Products under Development for Otitis Media, H2 2016
  • Number of Products under Development for Otitis Media - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Targets, H2 2016
  • Number of Products by Stage and Targets, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top